Company Profile

Company Profile

  • Company Profile

    Labyrinth Biotech is a precision oncology company based in Suzhou Industrial Park, advancing cancer diagnostics through AI-powered liquid biopsy and rare cell technologies.

    Our 26-member team and expert advisors—many with backgrounds from Fortune 500 pharmaceutical companies and leading institutions such as Yale, Harvard, MIT, and Peking University—bring deep expertise in precision medicine, microfluidics, and data-driven healthcare.

    Backed by over 40 patents (20+ granted) and operating under NMPA, FDA, CE, and ISO 13485 standards, we deliver scalable, non-invasive solutions to enable personalized, real-time cancer care worldwide.


Growth & Development

Growth & Development

2025

•Collaborate with the National University of Singapore

NUS.jpg

2024

•Collaborate with the Second Affiliated Hospital of Nanchang University, Sun Yat Sen University Cancer Hospital, Fudan University Cancer Hospital, the First Affiliated Hospital of Soochow University 

•CE01 PRO update

•Won the 2024 Future Medical Top 100 Selection Medical and Health Industry Innovation Product List

wechat_2025-08-04_163239_408.png

2023

•ISO 13485 Certification  •CE Registration 

•National High-Tech Enterprise 

•POCT CRO contract worth of millions with MolArray

Deep cooperation with Peking Union Medical College Hospital on precision medicine

wechat_2025-08-04_163116_362.png

2022

•First automatic prototype 

•NMPA & FDA Registration 

 •clinical trial projects with the First Affiliated Hospital of the University of Science and Technology of China

wechat_2025-08-04_162208_287.png

2021

•Gusu Leading Talent Enterprise 

•Start providing clinical and research services 

•overseas sales of chips

图片3.png

2020

•Suzhou Industrial Park Jinji Lake Technology Leading Talent

图片2.png

2019

•first place in China's Medical Device Innovation Competition

图片1.png

Mission and Vision

Mission and Vision

  • Mission

    Mission

    To transform cancer diagnostics through Al-powered CTCliquid biopsy technologies-delivering accurate, real-time,and non-invasive solutions for early detection and treatment monitoring across China and beyond.

  • Vision

    Vision

    To lead the global shift toward precision oncology by making CTC-based liquid biopsy the new clinical standard-bridging cutting-edge science with scalable impact across healthcare systems worldwide.

Core Team

Core Team

Scientific Advisor

Scientific Advisor

Cooperation Partners

Cooperative Partner

Honor

Honor

  • 1st Prize Award Certificate, China Medical Device Innovation Competition 2019

    1st Prize Award Certificate, China Medical Device Innovation Competition 2019

  • 1st Prize Trophy, 2019 China Medical Device Innovation Competition

    1st Prize Trophy, 2019 China Medical Device Innovation Competition

  • SIP Jinji Lake Technology Leading Talent

    SIP Jinji Lake Technology Leading Talent

  • The 2024 Future Medical Top 100 Selection Medical and Health Industry Innovation Product List

    The 2024 Future Medical Top 100 Selection Medical and Health Industry Innovation Product List

  • National High-Tech Enterprise

    National High-Tech Enterprise

  • Jiangsu Private Science & Technology Enterprise

    Jiangsu Private Science & Technology Enterprise

  • Jiangsu Provincial Innovative SME

    Jiangsu Provincial Innovative SME

Patent

Patent

Patent paper
Patent paper
Patent paper
Patent paper
Patent paper
Patent paper
Patent paper